Literature DB >> 14996843

Antithrombin-mediated anticoagulant activity of sulfated polysaccharides: different mechanisms for heparin and sulfated galactans.

Fábio R Melo1, Mariana S Pereira, Débora Foguel, Paulo A S Mourão.   

Abstract

We investigated the mechanisms of anticoagulant activity mediated by sulfated galactans. The anticoagulant activity of sulfated polysaccharides is achieved mainly through potentiation of plasma cofactors, which are the natural inhibitors of coagulation proteases. Our results indicated the following. 1) Structural requirements for the interaction of sulfated galactans with coagulation inhibitors and their target proteases are not merely a consequence of their charge density. 2) The structural basis of this interaction is complex because it involves naturally heterogeneous polysaccharides but depends on the distribution of sulfate groups and on monosaccharide composition. 3) Sulfated galactans require significantly longer chains than heparin to achieve anticoagulant activity. 4) Possibly, it is the bulk structure of the sulfated galactan, and not a specific minor component as in heparin, that determines its interaction with antithrombin. 5) Sulfated galactans of approximately 15 to approximately 45 kDa bind to antithrombin but are unable to link the plasma inhibitor and thrombin. This last effect requires a molecular size above 45 kDa. 6) Sulfated galactan and heparin bind to different sites on antithrombin. 7) Sulfated galactans are less effective than heparin at promoting antithrombin conformational activation. Overall, these observations indicate that a different mechanism predominates over the conformational activation of antithrombin in ensuring the antithrombin-mediated anticoagulant activity of the sulfated galactans. Possibly, sulfated galactan connects antithrombin and thrombin, holding the protease in an inactive form. The conformational activation of antithrombin and the consequent formation of a covalent complex with thrombin appear to be less important for the anticoagulant activity of sulfated galactan than for heparin. Our results demonstrate that the paradigm of heparin-antithrombin interaction cannot be extended to other sulfated polysaccharides. Each type of polysaccharide may form a particular complex with the plasma inhibitor and the target protease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996843     DOI: 10.1074/jbc.M308688200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2007-02-09       Impact factor: 3.228

2.  Anticoagulant activity of a unique sulfated pyranosic (1->3)-β-L-arabinan through direct interaction with thrombin.

Authors:  Paula V Fernández; Irene Quintana; Alberto S Cerezo; Julio J Caramelo; Laercio Pol-Fachin; Hugo Verli; José M Estevez; Marina Ciancia
Journal:  J Biol Chem       Date:  2012-11-16       Impact factor: 5.157

3.  Anticoagulation and antiplatelet effects of a dolastane diterpene isolated from the marine brown alga Canistrocarpus cervicornis.

Authors:  Laura de Andrade Moura; Everson Miguel Bianco; Renato Crespo Pereira; Valéria Laneuville Teixeira; André Lopes Fuly
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

4.  Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.

Authors:  Bianca F Glauser; Ricardo M Rezende; Fabio R Melo; Mariana S Pereira; Ivo M B Francischetti; Robson Q Monteiro; Alireza R Rezaie; Paulo A S Mourão
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

Review 5.  The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19.

Authors:  Tatyana A Kuznetsova; Boris G Andryukov; Ilona D Makarenkova; Tatyana S Zaporozhets; Natalya N Besednova; Ludmila N Fedyanina; Sergey P Kryzhanovsky; Mikhail Yu Shchelkanov
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

Review 6.  Fucanomics and galactanomics: marine distribution, medicinal impact, conceptions, and challenges.

Authors:  Vitor H Pomin
Journal:  Mar Drugs       Date:  2012-03-29       Impact factor: 6.085

Review 7.  Marine polysaccharides from algae with potential biomedical applications.

Authors:  Maria Filomena de Jesus Raposo; Alcina Maria Bernardo de Morais; Rui Manuel Santos Costa de Morais
Journal:  Mar Drugs       Date:  2015-05-15       Impact factor: 5.118

8.  Comparison of physicochemical characteristics and anticoagulant activities of polysaccharides from three sea cucumbers.

Authors:  Lan Luo; Mingyi Wu; Li Xu; Wu Lian; Jingying Xiang; Feng Lu; Na Gao; Chuang Xiao; Shengmin Wang; Jinhua Zhao
Journal:  Mar Drugs       Date:  2013-02-05       Impact factor: 5.118

9.  Short-term effects of amelogenin gene splice products A+4 and A-4 implanted in the exposed rat molar pulp.

Authors:  Nadège Jegat; Dominique Septier; Arthur Veis; Anne Poliard; Michel Goldberg
Journal:  Head Face Med       Date:  2007-12-21       Impact factor: 2.151

10.  Sphingosines Derived from Marine Sponge as Potential Multi-Target Drug Related to Disorders in Cancer Development.

Authors:  Renata Biegelmeyer; Rafael Schröder; Douglas F Rambo; Roger R Dresch; João L F Carraro; Beatriz Mothes; José Cláudio F Moreira; Mário L C da Frota Junior; Amélia T Henriques
Journal:  Mar Drugs       Date:  2015-08-25       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.